{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-009034","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.119137+00:00","generated_at":"2026-06-06T11:34:38.492320+00:00","sec_items":["1.02","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Allarity: Novartis terminates dovitinib license; director Cullem resigns citing misconduct","bullets":["Novartis terminated dovitinib license on Jan 26, 2024 citing material breach for lack of payment.","Director James G. Cullem resigned Jan 27, 2024, alleging acts and omissions by Chairman and Board injurious to company.","Cullem was terminated as CEO for cause on Dec 8, 2023; he claims termination should be without cause.","Allarity disagrees with Cullem's claims and takes exception to his characterizations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-009034","json":"https://secwatch.observer/filing/0001213900-24-009034.json","markdown":"https://secwatch.observer/filing/0001213900-24-009034.md","text":"https://secwatch.observer/filing/0001213900-24-009034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/ea192600-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:34:38.492320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d2b3a32a1","claim":"James G. Cullem resigned as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"On January 27, 2024, the Chairman of our Board of Directors (the “Board”), received email correspondence from Mr. James G. Cullem tendering his resignation (the “Resignation Email”) as a member of our Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"60badcc469615f6061d2177b40dc614205228504","claim":"Allarity Therapeutics, Inc. terminated Agreement with Novartis Pharma AG (effective 2024-01-26).","evidence_excerpt":"On January 26, 2024, we received written notice from Novartis indicating their decision to terminate the Agreement based on material breach for lack of financial payment.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Novartis Pharma AG"},{"label":"Effective","value":"2024-01-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}